Encouragingly and along these same lines, in early trials of anti-CD19 CAR therapy, infusions of modified, polyclonal donor-derived cells that were collected from the recipient (post-transplant) did not cause GvHD, possibly because of tolerance developed within the host[145, 146]. This evidence concerns the gene CD19 and graft versus host disease.